Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Duke-Margolis Center for Health Policy, Durham, North Carolina, USA.
Thyroid. 2022 Jan;32(1):54-64. doi: 10.1089/thy.2021.0285. Epub 2021 Dec 3.
Graves' disease accounts for ∼80% of all cases of hyperthyroidism and is associated with significant morbidity and decreased quality of life. Understanding the association of total thyroidectomy with patient-reported quality-of-life and thyroid-specific symptoms is critical to shared decision-making and high-quality care. We estimate the change in patient-reported outcomes (PROs) before and after surgery for patients with Graves' disease to inform the expectations of patients and their physicians. PROs using the MD Anderson Symptom Inventory (MDASI) validated questionnaire were collected prospectively from adult patients with Graves' disease from January 1, 2015, to November 20, 2020, on a longitudinal basis. Survey responses were categorized as before surgery (≤120 days), short term after surgery (<30 days; ST), and long term after surgery (≥30 days; LT). Negative binomial regression was used to estimate the association of select covariates with PROs. Eighty-five patients with Graves' disease were included. The majority were female (83.5%); 47.1% were non-Hispanic white and 35.3% were non-Hispanic black. The median thyrotropin (TSH) value before surgery was 0.05, which increased to 0.82 in ST and 1.57 in LT. In bivariate analysis, the Total Symptom Burden Score, a composite of all patient-reported burden, significantly reduced shortly after surgery (before surgery mean of 56.88 vs. ST 39.60, < 0.001), demonstrating improvement in PROs. Furthermore, both the Thyroid Symptoms Score, including patient-reported thermoregulation, palpitations, and dysphagia, and the Quality-of-Life Symptom Score improved in ST and LT (thyroid symptoms, before surgery 13.88 vs. ST 8.62 and LT 7.29; quality of life, before surgery 16.16 vs. ST 9.14 and LT 10.04, all < 0.05). After multivariate adjustment, the patient-reported burden in the Thyroid Symptom Score and the Quality-of-Life Symptom Score exhibited reduction in ST (thyroid symptoms, rate ratio [RR] 0.55, confidence interval [CI]: 0.42-0.72; quality of life, RR 0.57, CI: 0.40-0.81) and LT (thyroid symptoms, RR 0.59, CI: 0.44-0.79; quality of Life, RR 0.43, CI: 0.28-0.65). Quality of life and thyroid-specific symptoms of Graves' patients improved significantly from their baseline before surgery to both shortly after and longer after surgery. This work can be used to guide clinicians and patients with Graves' disease on the expected outcomes following total thyroidectomy.
格雷夫斯病占所有甲状腺功能亢进症病例的 80%左右,与显著的发病率和生活质量下降有关。了解全甲状腺切除术与患者报告的生活质量和甲状腺特异性症状之间的关联对于共同决策和高质量的护理至关重要。我们估计格雷夫斯病患者手术前后的患者报告结局 (PROs) 变化,以告知患者及其医生的预期。PROs 使用经 MD 安德森症状量表 (MDASI) 验证的问卷,从 2015 年 1 月 1 日至 2020 年 11 月 20 日,以纵向方式前瞻性收集格雷夫斯病成年患者的 PROs。调查答复分为手术前 (≤120 天)、短期术后 (<30 天;ST) 和长期术后 (≥30 天;LT)。使用负二项式回归估计选择协变量与 PROs 的关联。85 例格雷夫斯病患者被纳入研究。大多数是女性 (83.5%);47.1%是非西班牙裔白人,35.3%是非西班牙裔黑人。手术前促甲状腺激素 (TSH) 值中位数为 0.05,ST 时增加到 0.82,LT 时增加到 1.57。在单变量分析中,总症状负担评分,所有患者报告负担的综合评分,在手术后短期内显著降低 (手术前平均 56.88 分,ST 为 39.60 分, < 0.001),表明 PROs 有所改善。此外,甲状腺症状评分包括患者报告的体温调节、心悸和吞咽困难,以及生活质量症状评分在 ST 和 LT 中均有所改善 (甲状腺症状,手术前 13.88 分,ST 为 8.62 分,LT 为 7.29 分;生活质量,手术前 16.16 分,ST 为 9.14 分,LT 为 10.04 分,均 < 0.05)。多变量调整后,甲状腺症状评分和生活质量症状评分中的患者报告负担在 ST (甲状腺症状,RR 0.55,置信区间 [CI]:0.42-0.72;生活质量,RR 0.57,CI:0.40-0.81) 和 LT (甲状腺症状,RR 0.59,CI:0.44-0.79;生活质量,RR 0.43,CI:0.28-0.65) 中均有减少。格雷夫斯病患者的生活质量和甲状腺特异性症状从手术前基线显著改善到手术后短期和长期。这项工作可以用于指导格雷夫斯病患者的临床医生和患者进行全甲状腺切除术的预期结果。